Rare cancer-specific mutations in PIK3CA show gain of function

作者: M. Gymnopoulos , M.-A. Elsliger , P. K. Vogt

DOI: 10.1073/PNAS.0701005104

关键词:

摘要: Fifteen rare cancer-derived mutants of PIK3CA, the gene coding for catalytic subunit p110α phosphatidylinositol 3-kinase (PI3K), were examined their biological and biochemical properties. Fourteen these show a gain function: they induce rapamycin-sensitive oncogenic transformation chicken embryo fibroblasts, constitutively activate Akt TOR-mediated signaling, enhanced lipid kinase activity. Mapping on partial structural model suggests three groups mutants, defined by location in distinct functional domains protein. We hypothesize that each induces PI3K function different molecular mechanism. Mutants C2 domain increase positive surface charge this therefore may enhance recruitment to cellular membranes. helical map contiguous protein affect interaction with other protein(s). are located near hinge activation loop. They alter position mobility Arbitrarily introduced mutations have no detectable phenotype either interior or positioned region lies opposite exposed surfaces containing gain-of-function mutants. Engineered exchange acidic neutral residues basic critical function.

参考文章(30)
Yardena Samuels, Victor E. Velculescu, Oncogenic Mutations of PIK3CA in Human Cancers Cell Cycle. ,vol. 3, pp. 1221- 1224 ,(2004) , 10.4161/CC.3.10.1164
Guojun Wu, Mingzhao Xing, Elizabeth Mambo, Xin Huang, Junwei Liu, Zhongmin Guo, Aditi Chatterjee, David Goldenberg, Susanne M Gollin, Saraswati Sukumar, Barry Trink, David Sidransky, Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Research. ,vol. 7, pp. 1- 8 ,(2005) , 10.1186/BCR1262
Maria Antonietta Cerone, Ryan J Ward, J. Arturo Londoño-Vallejo, Chantal Autexier, Telomerase RNA mutated in autosomal dyskeratosis congenita reconstitutes a weakly active telomerase enzyme defective in telomere elongation. Cell Cycle. ,vol. 4, pp. 578- 582 ,(2005) , 10.4161/CC.4.4.1586
B Karakas, K E Bachman, B H Park, Mutation of the PIK3CA oncogene in human cancers. British Journal of Cancer. ,vol. 94, pp. 455- 459 ,(2006) , 10.1038/SJ.BJC.6602970
Masahiro Aoki, Christian Schetter, Martin Himly, Osvaldo Batista, Hwai Wen Chang, Peter K. Vogt, The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. Journal of Biological Chemistry. ,vol. 275, pp. 6267- 6275 ,(2000) , 10.1074/JBC.275.9.6267
J. P. Walsh, K. K. Caldwell, P. W. Majerus, Formation of phosphatidylinositol 3-phosphate by isomerization from phosphatidylinositol 4-phosphate. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 88, pp. 9184- 9187 ,(1991) , 10.1073/PNAS.88.20.9184
J B Easton, P J Houghton, mTOR and cancer therapy. Oncogene. ,vol. 25, pp. 6436- 6446 ,(2006) , 10.1038/SJ.ONC.1209886
Sandrine Faivre, Guido Kroemer, Eric Raymond, Current development of mTOR inhibitors as anticancer agents Nature Reviews Drug Discovery. ,vol. 5, pp. 671- 688 ,(2006) , 10.1038/NRD2062
Douglas A. Levine, Faina Bogomolniy, Cindy J. Yee, Alex Lash, Richard R. Barakat, Patrick I. Borgen, Jeff Boyd, Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers Clinical Cancer Research. ,vol. 11, pp. 2875- 2878 ,(2005) , 10.1158/1078-0432.CCR-04-2142
Jeffrey A. Engelman, Ji Luo, Lewis C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nature Reviews Genetics. ,vol. 7, pp. 606- 619 ,(2006) , 10.1038/NRG1879